spacer
home > ebr > autumn 2018 > oncological advances
PUBLICATIONS
European Biopharmaceutical Review

Oncological Advances

Cancer is constantly evolving. It initiates, spreads, and evades therapies. Fortunately, oncology has always been a field of innovation where methods to detect, diagnose, and treat cancer are continuously advancing. In fact, mortality rates across the US and Europe are dropping, with nearly 5 million more US citizens projected to survive cancer in 2026 than in 2016, according to the National Cancer Institute (1). These increases in survival are, in part, due to greater rates of early detection, stemming from innovative imaging techniques and preventative measures, such as smoking cessation and vaccines against cancer-causing viruses. Additionally, the identification of tumour suppressors and oncogenes has aided in better drug development, and matching patients to targeted therapies based on tumour genetics has led to improved survival rates.

Today’s wave of innovation centres around technology and Big Data. Big Data represents a body of information that is too large and too complex to be analysed by traditional data processing software. In the medical field, Big Data comes in the form of electronic health records, genetic and genomic sequencing, and an ever-increasing body of medical literature. Big Data and technology go hand-in-hand, as equipment is being developed to both generate and analyse Big Data. With Big Data’s introduction, the field of oncology is adding new technology to cancer prevention, diagnosis, and treatment options for patients. Some outstanding innovations are discussed in this article.

Next Generation Sequencing (NGS)

NGS is high-throughput sequencing that enables entire genomes, exomes, and cancer-relevant gene panels to be sequenced at an unprecedented rate for an increasingly affordable price. NGS is now routinely used to facilitate precision cancer therapy: the practice of matching a therapy to a patient based on the specific molecular or clinical characteristics of the individual. New initiatives are being undertaken to sequence the entire genome of large populations (eg, 100,000 Genomes Project, All of Us, and Médecine Génomique 2025). Such projects are expected to reveal associations useful for cancer prevention, differential diagnoses, and drug development. Pharmacogenomics is another primary objective with such large-scale studies certain to define variants associated with response and others with resistance to therapy. However, large-scale sequencing alone is not enough.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Kathryn D Bungartz is a Principal Scientist at precision medicine company, N-of-One. Prior to joining the company, Kathryn enjoyed an international scientific career in the field of extracellular matrix, and later served as Content Editor of the American Journal of Human Genetics. Stations of her career include the Max Planck Institute for Biochemistry, Germany, The University of Pennsylvania, US, and Harvard University, US. Kathryn currently resides in Europe part-time, where she heads a course in medical writing.
spacer
Dr Kathryn D Bungartz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement